Gilead Sciences Inc (GILD)
$127.74+3.15%
Spriggl Score: Good— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“HIV franchise secured to 2036; two next-generation drug approvals expected this year; income and pipeline compelling.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Gilead Sciences Inc
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor …
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - General
- Market Cap:
- $155.8B
Recent dividends
- 15 Jun 2026$0.82
- 13 Mar 2026$0.82
- 15 Dec 2025$0.79
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Gilead Sciences Inc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free